GlaxoSmithKline (GSK ) has acknowledged that some senior employees in the firm were allegedly involved in a bribing scandal of doctors prescribing the firm's drugs in China.
According to the BBC, senior executives in GSK's China office appeared to have been using travel agencies to bribe government officials, doctors and hospitals in order to boost sales and prices of their drugs.
GSK is now co-operating with a Chinese investigation into the probe and several GSK employees have been detained by the Chinese police, the report added.
GSK's British head of finance in China, Steve Nechelput, has been subjected to a travel ban since the end of June.
You’ve reached your limit of 5 free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app